Compare SOBR & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOBR | SBFM |
|---|---|---|
| Founded | 2004 | 2006 |
| Country | United States | United States |
| Employees | 18 | N/A |
| Industry | Newspapers/Magazines | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8M | 3.3M |
| IPO Year | 2008 | 2008 |
| Metric | SOBR | SBFM |
|---|---|---|
| Price | $1.00 | $75.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 273.1K | ★ 457.2K |
| Earning Date | 04-10-2026 | 04-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 103.55 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $437,421.00 | ★ $36,305,891.00 |
| Revenue This Year | N/A | $40.47 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 105.62 | 4.11 |
| 52 Week Low | $0.35 | $0.25 |
| 52 Week High | $3.95 | $3.05 |
| Indicator | SOBR | SBFM |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Sobr Safe Inc is a hardware and software company. The Company integrates proprietary software, SOBRsafeTM, with its patented touch-based personal alcohol awareness tracking products, SOBRcheckTM and SOBRsure, enabling non-invasive personal alcohol awareness tracking, biometric identity verification, and qualified, real-time cloud-based, informational alerts and reporting. It operates as a single segment designed to enable customers to purchase products directly through channel partners, sales agents or through its enterprise and consumer digital channels. Currently its principal markets are located in North America.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.